Literature DB >> 12677168

Modifier genes in cystic fibrosis lung disease.

Christian A Merlo1, Michael P Boyle.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene and is characterized by progressive bronchiectatic lung disease and pancreatic exocrine insufficiency. A broad spectrum of disease severity exists; some individuals with CF die early in childhood, whereas others live well into adulthood with only mild lung disease. It is now clear that CFTR genotype alone does not account for the wide diversity in CF pulmonary phenotype. Evidence is accumulating that secondary genetic factors separate from the CFTR locus significantly influence the severity of CF lung disease. The general classes of these potential modifier genes include inflammatory and antiinflammatory mediators, antioxidants, mediators of airway reactivity, molecules involved in CFTR trafficking, and alternative ion channels. The best-studied CF candidate modifiers include mannose-binding lectin, glutathione-S-transferase, transforming growth factor-beta1, tumor necrosis factor-alpha, beta2-adrenegic receptor, and HLA class II antigens. Ongoing studies designed to identify genetic modifiers of CF pulmonary phenotype may offer new insights into the pathophysiology of CF lung disease and provide leads for new CF therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12677168     DOI: 10.1067/mlc.2003.29

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  16 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

2.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 3.  Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.

Authors:  Kevin G Chen; Pingyu Zhong; Wei Zheng; Jeffrey M Beekman
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

Review 4.  Neural plasticity, human genetics, and risk for alcohol dependence.

Authors:  Shirley Y Hill
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

5.  Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness.

Authors:  Tao Sun; Zhe Sun; Yale Jiang; Annabel A Ferguson; Joseph M Pilewski; Jay K Kolls; Wei Chen; Kong Chen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-11       Impact factor: 6.914

6.  Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease.

Authors:  Jerry M Wright; Christian A Merlo; Jeffrey B Reynolds; Pamela L Zeitlin; Joe G N Garcia; William B Guggino; Michael P Boyle
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-13       Impact factor: 6.914

Review 7.  Atypical cystic fibrosis and CFTR-related diseases.

Authors:  Shruti M Paranjape; Pamela L Zeitlin
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

8.  Laboratory evolution of adenylyl cyclase independent learning in Drosophila and missing heritability.

Authors:  M Cressy; D Valente; A Altick; E Kockenmeister; K Honegger; H Qin; P P Mitra; J Dubnau
Journal:  Genes Brain Behav       Date:  2014-06-19       Impact factor: 3.449

9.  Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.

Authors:  K Czerska; A Sobczynska-Tomaszewska; D Sands; A Nowakowska; D Bak; K Wertheim; J Poznanski; J Zielenski; A Norek; J Bal
Journal:  J Appl Genet       Date:  2010       Impact factor: 2.653

10.  Saturation of the human phenome.

Authors:  Mark E Samuels
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.